Xenetic Biosciences Inc. (XBIO) is priced at $1.16 after the most recent trading session. At the very opening of the session, the stock price was $1.02 and reached a high price of $1.04, prior to closing the session it reached the value of $1.01. The stock touched a low price of $1.00.
Recently in News on November 13, 2020, Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update. – Continued Advancement of XCART™ Platform Towards an IND Filing and Phase 1 Study. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Xenetic Biosciences Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.8500 on 01/22/20, with the lowest value was $0.4400 for the same time period, recorded on 03/19/20.
Xenetic Biosciences Inc. (XBIO) full year performance was -18.91%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Xenetic Biosciences Inc. shares are logging -37.03% during the 52-week period from high price, and 164.77% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.44 and $1.85.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1196794 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Xenetic Biosciences Inc. (XBIO) recorded performance in the market was -29.86%, having the revenues showcasing -1.94% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 6.10M, as it employees total of 4 workers.
Market experts do have their say about Xenetic Biosciences Inc. (XBIO)
During the last month, 0 analysts gave the Xenetic Biosciences Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.0041, with a change in the price was noted +0.1350. In a similar fashion, Xenetic Biosciences Inc. posted a movement of +13.43% for the period of last 100 days, recording 416,884 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for XBIO is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Xenetic Biosciences Inc. (XBIO)
Raw Stochastic average of Xenetic Biosciences Inc. in the period of last 50 days is set at 80.85%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 80.85%. In the last 20 days, the company’s Stochastic %K was 81.73% and its Stochastic %D was recorded 79.50%.
Bearing in mind the latest performance of Xenetic Biosciences Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -29.86%. Additionally, trading for the stock in the period of the last six months notably improved by 2.55%, alongside a downfall of -18.91% for the period of the last 12 months. The shares increased approximately by 17.24% in the 7-day charts and went down by 20.94% in the period of the last 30 days. Common stock shares were lifted by -1.94% during last recorded quarter.